This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
|Articles|September 16, 2010
Regulatory Roundup: ISPE to Hold Risk-MaPP 2010 Conference
Author(s)Pharmaceutical Technology Editors
ISPE to Hold Risk-MaPP 2010 Conference
Advertisement
The International Society for Pharmaceutical Engineering (ISPE) will host the ISPE Risk-MaPP 2010 Conference, Dedicated Facilities, Cross Contamination and the Risk-MaPP Approach in Washington, DC, on October 4–5 2010. The group will hold the North American launch of the new ISPE Baseline Guide: Risk-Based Manufacturing of Pharmaceutical Products (Risk-MaPP) at the conference, and attendees will receive a complimentary downloadable copy of the guide. To register for the conference, click
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement